Details

Titel

Cancer Drug News

Ist Teil von

• Cancer Drug News Newsletter, 2017 (6 NOVEMBER 2017)

Erscheinungsjahr

2017

Link zum Volltext

Beschreibungen/Notizen

• Industry Trend Analysis - Celgene Will Still Record Growth Despite Missed Targets Industry Trend Analysis - Calquence Will Not Match Imbruvica's Revenues Industry Brief - KHK's MAA For Mogamulizumab To Treat CTCL Validated By EMA Industry Brief - Seattle Genetics Submits sBLA For Adcetris In Frontline Advanced Hodgkin’s Lymphoma Industry Brief - Jazz Submits Vyxeos MAA To EMA To Treat AML Industry Trend Analysis - Adding Breadth To Oncomine Will Aid Thermo Fisher Develop Universal Diagnostic Status Industry Brief - FDA Grants ODD To Merrimack's MM-121 In Advanced NSCLC Industry Brief - Incyte/MedImmune Enter Clinical Trial Collaboration In NSCLC Industry Brief - Chi-Med Initiates Fruquintinib Phase III Trial in Second-Line GOJ Cancer Industry Brief - EMA Validates BMS' Type II Variation Application For Opdivo In Advanced Melanoma Industry Brief - NewLink Genetics Receives FDA ODD For Indoximod In Melanoma Industry Brief - Daiichi Sankyo/Glycotope Enter Option Agreement For ADC Industry Brief - Y-mAbs Completes Equity Fundraising Industry Brief - Evotec/Tesaro Enter Immuno-Oncology Drug-Discovery Collaboration Industry Brief - Phase III Study Of Pexidartinib Meets Primary Endpoint In TGCT Industry Brief - VBL And NanoCarrier Sign Exclusive Agreement For VB-111 In Japan Industry Brief - Vedantra Extends Research Collaboration With Neon Therapeutics Industry Trend Analysis - Opdivo Continues To Drive BMS' Sales Outlook